Abstract

Simple SummaryThymic epithelial tumours are uncommon malignancies. Histologically, they may be distinguished in different subtypes and different relapse risk classes. Surgery, sometimes after induction therapy, stays the best treatment option, and long-term results depend on the disease stage and completeness of resection. In this context, 18F FDG PET CT scan has been reported to play different roles in the care strategy of thymic epithelial tumours. In the present review, we analyse current evidences, the use of this imaging tool and future application prospects.Background: The use of 18F FDG PET/CT scan in thymic epithelial tumours (TET) has been reported in the last two decades, but its application in different clinical settings has not been clearly defined. Methods: We performed a pictorial review of pertinent literature to describe different roles and applications of this imaging tool to manage TET patients. Finally, we summarized future prospects and potential innovative applications of PET in these neoplasms. Results: 18FFDG PET/CT scan may be of help to distinguish thymic hyperplasia from thymic epithelial tumours but evidences are almost weak. On the contrary, this imaging tool seems to be very performant to predict the grade of malignancy, to a lesser extent pathological response after induction therapy, Masaoka Koga stage of disease and long-term prognosis. Several other radiotracers have some application in TETs but results are limited and almost controversial. Finally, the future of PET/CT and theranostics in TETs is still to be defined but more detailed analysis of metabolic data (such as texture analysis applied on thymic neoplasms), along with promising preclinical and clinical results from new “stromal PET tracers”, leave us an increasingly optimistic outlook. Conclusions: PET plays different roles in the management of thymic epithelial tumours, and its applications may be of help for physicians in different clinical settings.

Highlights

  • Thymic epithelial tumours (TETs) arise from the thymus and represent approximately0.2–1.5% of all malignancies [1–3]

  • Lee et al [29] investigated the role of SUVmax, average standardized uptake values (SUV), metabolic tumour volume (MTV) and total glycolytic volume (TGV), pointing out a significant difference comparing these parameters in the different Masaoka Koga stages

  • In 2014, Seki et al assessed the correlation between 18 F-FDG positron emission tomography (PET)/computed tomography (CT) findings and long-term results in 37 patients surgically treated for TETs

Read more

Summary

Introduction

Thymic epithelial tumours (TETs) arise from the thymus and represent approximately. 0.2–1.5% of all malignancies [1–3]. Considering histological characteristics and survival outcome, it is possible to categorize TETs in different risk classes, with a low risk class including types A, AB, and B1, and a high risk class including. TETs are usually studied using computed tomography (CT) and magnetic resonance imaging (MRI) to categorize mediastinal lesions [13,14], but these two instruments present limitations to distinguish between the histological subtypes of TETs [15,16]. Regarding this point, the use of fluorine-18-fluorodeoxyglucose (18 F-FDG) positron emission tomography (PET) and PET/CT rapidly increased for the evaluation of TETs.

PET/CT to Distinguish Thymic Hiperplasia from Thymic Epithelial Tumours
PET/CT to Stage Thymic Epithelial Tumours
PET/CT to Predict the Grade of Malignancy of Thymic Epithelial Tumours
PET/CT to Predict Pathological Response after Induction Therapy
PET/CT to Predict Prognosis
Among other factors (Masaoka
Other PET/CT Radiopharmaceuticals in Thymic Epithelial Tumours
Future Perspectives
Findings
Conclusions
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call